NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»15/10/2009 [Industry news]
DIA to host first China meeting in Beijing on Nov 1-3

The Drug Information Association (DIA), in collaboration with the China Center for Pharmaceutical International Exchange of the SFDA, will host the First China Annual Meeting: Drug Development in a Flat World—Innovation, Regulation and Globalization in Beijing, China.

 
The Drug Information Association (DIA), in collaboration with the China Center for Pharmaceutical International Exchange of the SFDA, will host the First China Annual Meeting: Drug Development in a Flat World—Innovation, Regulation and Globalization in Beijing, China. Speakers from major regulatory agencies, industry, and academia will lead workshops and sessions on how drug development impacts China as the country takes on an increasingly preeminent role in the global arena. Session topics will include: Drug Development and Regulation in the 21st Century, Simultaneous Global Development and Multiregional Trials, Evolving Innovation Ecology and Innovation Cluster in China, Transformational Bioinformatics, Good Regulatory Practice, Biosimilars, Developing High-quality Clinical Study Sites Ethical Review of Clinical Trials, Implementation of Global GCP Standards, and Biometrics in China Prof Sang Guowei, Vice Chairman, Standing Committee of the National People’s Congress of PRC and Member, Chinese Academy of Engineering, China, will deliver the keynote address titled, “The Pharmaceutical Industry and Innovative Drug and R&D in China Under the Environment of Financial Crisis.” Mr Shao Mingli, Commissioner of the SFDA, will address the conference in the opening session. Several representatives from the SFDA, FDA, EMEA, PMDA, KFDA, and TGA, will participate in presentations and discussions. Dr Ling Su, Program Co-chair and Vice President, Clinical Research and Development, Asia Pacific, Wyeth, China, said “There is no doubt that drug discovery, development, and regulation is becoming more and more globalized and China is playing an increasingly important role in this new paradigm. This inaugural DIA China Annual Meeting will serve as an international and neutral forum to examine important issues in global drug development and their relevance to China.” Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.